![Michal Ayalon](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Michal Ayalon worked as Vice President of Research and Development at Kamada Ltd. from 2019 to 2022.
Prior to that, she held the same position at Galmed Pharmaceuticals Ltd. in 2015-2016.
In 2018-2019, she was Head of Research and Development at 89Bio Ltd. Ayalon received her undergraduate, graduate, and doctorate degrees from Tel-Aviv University.
Anciens postes connus de Michal Ayalon
| Sociétés | Poste | Fin |
|---|---|---|
| KAMADA LTD. | Directeur Technique/Scientifique/R&D | 28/02/2022 |
89Bio Ltd.
 89Bio Ltd. Pharmaceuticals: MajorHealth Technology Develops therapies and drugs for treatments of patients living with nonalcoholic steatohepatitis | Directeur Technique/Scientifique/R&D | 01/01/2019 |
| GALMED PHARMACEUTICALS LTD. | Directeur Technique/Scientifique/R&D | 01/01/2016 |
Formation de Michal Ayalon
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
22
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Tel-Aviv University
 Tel-Aviv University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kamada Ltd.
 Kamada Ltd. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops and manufactures plasma-derived therapeutics products | Health Technology |
Galmed Pharmaceuticals Ltd.
 Galmed Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures aramchol for non-alcoholic steatohepatitis | Health Technology |
89Bio Ltd.
89Bio Ltd. Pharmaceuticals: MajorHealth Technology Develops therapies and drugs for treatments of patients living with nonalcoholic steatohepatitis | Health Technology |
